- Healthcare Professionals
- Research
- Clinical trials
- krt-232-115
Haematology
Haematology
2024-03-04T00:00:00.000+11:00
KRT-232-115
KRT-232-115
Haematology
KRT-232-115: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
KRT-232-115: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Trial overview
Disease
Haematology
Topic
Myleofibrosis
Sponsor
Kartos Therapeutics
Description
KRT-232-115: A Front-Line, Phase 3, Randomized, Double-Blind, Add-On Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Myelofibrosis Patients Who Have a Suboptimal Response to Ruxolitinib
Study details
details to follow
Trial status
Due to open October 24 in Oxford and Windsor
Priniciple Investigator
Dr Bethan Psalia - Oxford
Dr Pratap Neelakatan - Windsor